In today’s ever-evolving and highly regulated pharmaceutical landscape, managing regulatory affairs (RA) and pharmacovigilance (PV) has become a critical and resource-intensive responsibility.
Patient safety is a crucial part of healthcare that seeks to protect patients from harm during their treatment and care.
21 CFR 314.80 is a regulation established by the U.S. Food and Drug Administration (FDA) to govern the post marketing reporting of adverse drug experiences.
Adaptis is delighted to announce the signing of a Memorandum of Understanding (MoU) with Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune. This partnership aims to bridge the gap between academia and industry, fostering collaboration and expertise in the pharmaceutical sector.
With immense gratitude and joy, we celebrated the inauguration of our new office—a milestone made possible by unwavering support and blessings. The pooja and lamp-lighting ceremony symbolized the start of a journey filled with hope, unity, and ambition.
We are thrilled to have played a pivotal role in helping our client successfully clear their USFDA audit. Through our PV expertise in designing and implementing comprehensive Pharmacovigilance systems, strengthening SOP frameworks, and ensuring rigorous PV compliance...